TRISPECIFIC Antibody Discovery
Trispecific discovery simplified
Three binding specificities, one IgG-like platform. The T-Body platform broadens access to novel mechanisms of action, pushing the boundaries of antibody therapeutics.
Why 3 targets? Powerful therapeutics begin with a 3-pronged strategy
T-Body platform workflow is customized for your program. We have engineered multispecific ADCs, T-cell engagers, next-generation IO therapies, and more using this flexible solution.
Why choose trispecifics?
Mechanistic richness
One drug, three coordinated levers working in a single molecule. For example, simultaneous targeting of tumor, effector cell, and immunosuppressive pathway
Localization and transport
Amplify the benefits of bispecific antibody disease targeting by using a third arm to localize or transport the therapeutic to the desired disease location
Logic gating and selectivity
Multi-antigen tumor offers “AND/OR” logic in one scaffold for fine-tuned avidity and spatial control, preventing escape through downregulation of target expression or the ability to combine logic gates with different mechanisms of action to enhance efficacy
Resistance management:
Built-in redundancy across antigens or pathways, lowering escape risk without needing multiple products or complex combinations. When resistance is driven by pathway redundancy, trispecifics can block three nonredundant targets at once.
Target heterogeneous tumors:
Access broader patient populations with broader coverage therapies by targeting complementary tumor targets
Why invenra for trispecifics? Four reasons partners choose us for trispecifics
Most trispecific work runs into the same walls: engineering takes years, the platform fights you instead of helping, and you end up with one molecule that may or may not work. We built the T-Body platform to fix these issues and enable the next generation of therapeutics.
True partnership
You bring the biological insight; we bring trispecific engineering expertise and a proprietary platform tuned to deliver winning development candidates. We work closely with you to make a game-changing drug candidate.
Test configurations side by side
Multiple binding arms in multiple bispecific and/or trispecific configurations are tested in parallel. The ease of screening opens a larger design space, so you can find that rare combination that works for your program.
Built for many therapeutic areas
The platform is compatible with standard conjugation strategies and Fc modifications. It enables programs across oncology, immunology, neurology, and other disease areas.
Strategic partners welcome
From early-stage biotechs to large pharma seeking trispecific engineering they don’t have in-house. We structure the engagement to fit the program and the partner.
Behind the science Understanding the T-Body™ platform design
T-Body platform expands on the proven architectural principles used in our B-Body® bispecific platform by enabling a third specific Fab. This makes trispecific engineering more accessible to a wider range of therapeutics, including ADCs, T-cell engagers, next-generation immunotherapies, and more. Have a three-pronged therapeutic strategy in mind? Let’s explore it together.
- Proprietary CH3 domain pairs
Replace CH1/CL in two of the three Fab arms with two uniquely configured CH3 domain pairs. Solve light-chain mispairing and create natural isoelectric-point asymmetry for clean, straightforward purification. - Symmetrical chain inversions
Proprietary heavy- and light-chain arrangements in the Fab arms deliver robust expression and efficient purification. - Knobs-into-holes Fc
Clinically validated heavy chain heterodimerization. Compatible with standard Fc substitutions for effector function engineering. - Validated binding kinetics
BLI and SPR confirm simultaneous 3-antigen engagement. Each arm’s kinetics is independently assessed. Comparable performance between trispecifics and one-armed controls. - Custom trispecific formats
The platform flexibility allows nearly endless orientations, valencies, and formats.
18 variants from one tumor antigen
3 CD3 affinities × 3 CD28 affinities across 2 epitope bins × 2 molecular orientations — every combination built and tested in the final trispecific format
With tumor cells present — potency
The optimized trispecific (blue) was more potent than the corresponding bispecific (green) across cytotoxicity, CD8 T-cell activation, and cytokine release (IFNγ, IL-2, TNFα)
Without tumor cells — safety
Both the trispecific (blue) and bispecific (green) showed minimal CD8 T-cell fratricide and auto-activation, and no cytokine release in the absence of tumor cells.
Screen hundreds of bispecifics first
Per-cell-line killing at 4 nM for hundreds of bispecifics across Her2-low, Her2-high, and triple-negative lines. This screen finds the best bispecific target pairs, informing us which trispecifics should be built.
Then let the activity pick the winners
Formats compared head-to-head
Trispecifics (triangles, circled in green) cluster in the high-killing zone, past the 70% gates — ahead of bispecifics (circles) and one-armed controls (squares)
- By comparing B-Body bispecific and T-Body trispecific antibodies head to head, we can identify lead candidates.
- Trispecifics showed broader and more potent ADC killing than the bispecifics.
- Trispecific ADCs are expected to work better in heterogeneous tumors.
Optional add-ons Get deeper characterization
Most programs add structured characterization beyond what’s included in the matrix screening: biophysical, binding kinetics, and formulation. We run all of it in-house. You don’t need another outsourced partner or potential in-house lab delays.
BIO
Full biophysical + binding suite
Carterra LSA high-throughput binding kinetics and epitope diversity, validated cell binding analysis, in silico liability scanning, mass spec for intact mass confirmation, full developability assay panel, and high-concentration formulation optimization.
DEV
Extensive developability capabilities
Expression and purity, thermal stability, self-association, aggregation, solubility, immunogenicity risk, viscosity, each measured with a validated technique. The full developability data sits behind every lead candidate we hand off.